Whole Genome Sequencing Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028, Segmented By Sequencing Type (Large Whole-Genome Sequencing, Small Genome Sequencing), By Product Type (Instrument, Kits, Service), By Application (Diagnostics, Drug Discovery and Development, Personalized Medicine, Others), By End User (Hospitals and Clinics, Pharmaceutical and
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationWhole Genome Sequencing Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028, Segmented By Sequencing Type (Large Whole-Genome Sequencing, Small Genome Sequencing), By Product Type (Instrument, Kits, Service), By Application (Diagnostics, Drug Discovery and Development, Personalized Medicine, Others), By End User (Hospitals and Clinics, Pharmaceutical and
Whole Genome Sequencing Market is expected to grow with an impressive CAGR in the forecast period, 2024-2028.
Whole Genome Sequencing Market (WGS) technology can deliver quick results and high-quality data. It can be used to locate, monitor, and address disease outbreaks in a region. WGS is shown to be most useful in research and rarely in therapeutic treatments.
The mapping of novel organisms' genomes, the completion of the genomes of already-known organisms, or the comparison of genomes from other samples all benefiting from microbial whole-genome sequencing. To create reliable reference genomes, microbial identification, and other comparative genomic investigations, it is required to sequence the full bacterial, viral, and other microbial genomes.
Growing Technological Advancement
Increasing technological advancement in NGS instruments and update in technology utilized in Sequencing techniques is adding to further drive the sequencing market growth in the forecast period. Moreover, with its multiplexing feature, next-generation sequencing (NGS) enables microbiology researchers to sequence hundreds of organisms, unlike capillary sequencing or PCR-based methods. NGS-based microbial genome sequencing is time efficient and streamlines the workflow and does not rely on time-consuming cloning stages like older techniques. Additionally, low-frequency variations and genomic rearrangements that might be overlooked are too expensive to find using current techniques can be found using NGS (Next Generation Sequencing). Also, population-level WES (whole exome sequencing) data generation has increased in today’s time. The whole exome sequencing (WES) is a successful application in the field of sequencing and is proved by the discovery of the genes for the conditions such as Mendelian phenotypes, Miller’s disease and other diseases.
Download Free Sample ReportGrowing Demand in Disease Diagnosis
Whole genome sequencing has an increased demand in clinical applications regarding the disease diagnosis and has significant importance in identification of mutation in a genome segment for isolating a variant or mutation in a gene. Moreover,
Increased Application in Genome Mapping
The rising demand for genome mapping in government projects for the rising research and development related to disease diagnosis and research for improved treatment in cancer, mutated disorders, and other diseases, etc. Furthermore, governments of distinct countries and regions are sequencing millions of genomes to progress research and discover better ways to identify and cure cancer, uncommon disorders, and other ailments. For instance, the European government is undertaking efforts to improve the region’s large-scale genomic data with projects such as the France’s French Plan for Genomic Medicine 2025 and similarly, the United Kingdom’s 100,000 Genomes Project. These initiatives have resulted in the growth of NGS Next-generation sequencing (NGS) informatics services in the region. For instance, in November 2022, using Nanopore Genome Sequencing, AI, and Cloud Computing, the scientists at the Stanford Medicine University sequenced a patient's whole genome in under five hours.
Recent Development
- InNovember 2021, Illumina and Genetic Alliance announced a USD 120 million globalinitiative—iHope Genetic Health program. This initiative aims to offer WholeGenome Sequencing (WGS) access to various patients impacted by geneticdisorders globally.
- Also,In 2020, a leading company QIAGEN acquired the NeuMoDx Molecular and securedits position in the market in automatedmolecular testing. The company now includes medium- and high-throughput NeuMoDxautomation solutions based on PCR testing technology, as a new component of itsupdated product portfolio.
Market Segmentation
The whole Genome Sequencing Market is segmented based on the sequencing type, product type, application, end user, and region. Based on sequencing type, the market is segmented into large whole-genome sequencing and small genome sequencing. Based on product type, the market is segmented into instrument, kits, and service. Based on application, the market is segmented into diagnostics, drug discovery and development, personalized medicine, and others. Based on end user, the market is further fragmented into hospitals and clinics, pharmaceutical, and biotechnology companies, and others. Based on the region, the market is further segmented into North America, Europe, Asia-Pacific, South America, and MEA.
Market Players
GE Healthcare, Inc., Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific, Agilent Technologies, 10 x Genomics, BGI, Oxford Nanopore, Nebula Genomics, Veritas Genetics, etc.., are some of the major players operating in the global Whole Genome Sequencing Market.
| Attribute | Details |
| Base Year | 2022 |
| Historical Years | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | Sequencing Type Product Type Application End user |
| Regional Scope | North America; Asia Pacific; Europe; South America; Middle East & Africa |
| Country Scope | United States; Canada; Mexico; China; India; Japan; South Korea; Australia; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; Saudi Arabia; UAE; South Africa; Kuwait |
| Key Companies Profiled | GE Healthcare, Inc., Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific, Agilent Technologies, 10 x Genomics, BGI, Oxford Nanopore, Nebula Genomics, Veritas Genetics. |
| Customization Scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy